Hologic Completes Acquisition of Endomagnetics Ltd
Hologic (Nasdaq: HOLX) has completed its acquisition of Endomagnetics (Endomag), a UK-based developer of breast cancer surgery technologies, for approximately $310 million. This acquisition adds Endomag's wireless breast surgery localization and lymphatic tracing solutions to Hologic's breast surgery portfolio, including the Magseed® marker, Magtrace® lymphatic tracer, and Sentimag® platform.
The integration aims to provide breast surgeons and radiologists with an expanded range of options and enhanced user experience. Hologic's President of Breast and Skeletal Health Solutions, Erik Anderson, expressed enthusiasm about increasing access to Endomag's innovative technologies and improving outcomes for patients. Endomag's CEO, Eric Mayes, shared optimism about the opportunities for their team and the potential to impact more women globally.
Hologic (Nasdaq: HOLX) ha completato l'acquisizione di Endomagnetics (Endomag), un'azienda britannica che sviluppa tecnologie per la chirurgia del cancro al seno, per circa 310 milioni di dollari. Questa acquisizione aggiunge le soluzioni di localizzazione wireless per la chirurgia del seno e di tracciamento linfatico di Endomag al portafoglio chirurgico di Hologic, inclusi il marker Magseed®, il tracciante linfatico Magtrace® e la piattaforma Sentimag®.
L'integrazione ha l'obiettivo di fornire ai chirurghi e ai radiologi del seno una gamma ampliata di opzioni e una maggiore esperienza utente. Erik Anderson, Presidente di Hologic per le Soluzioni per la Salute del Seno e dello Scheletro, ha espresso entusiasmo riguardo all’aumento dell'accesso alle tecnologie innovative di Endomag e al miglioramento dei risultati per i pazienti. Eric Mayes, CEO di Endomag, ha condiviso ottimismo riguardo alle opportunità per il loro team e al potenziale di impattare un numero maggiore di donne a livello globale.
Hologic (Nasdaq: HOLX) ha completado su adquisición de Endomagnetics (Endomag), un desarrollador con sede en el Reino Unido de tecnologías para la cirugía del cáncer de mama, por aproximadamente 310 millones de dólares. Esta adquisición incorpora las soluciones de localización inalámbrica para la cirugía de mama y de rastreo linfático de Endomag al portafolio de cirugía de mama de Hologic, incluidos el marcador Magseed®, el rastreador linfático Magtrace® y la plataforma Sentimag®.
La integración tiene como objetivo proporcionar a los cirujanos de mama y a los radiólogos una gama ampliada de opciones y una experiencia de usuario mejorada. Erik Anderson, Presidente de Soluciones de Salud del Seno y Esquelético de Hologic, expresó su entusiasmo por aumentar el acceso a las tecnologías innovadoras de Endomag y por mejorar los resultados para los pacientes. Eric Mayes, CEO de Endomag, compartió optimismo sobre las oportunidades para su equipo y el potencial de impactar a más mujeres a nivel mundial.
홀로직(Hologic) (Nasdaq: HOLX)이 유방암 수술 기술을 개발하는 영국 기반의 기업인 앤도마그네틱스(Endomag)를 약 3억 1천만 달러에 인수했습니다. 이번 인수로 홀로직의 유방 수술 포트폴리오에 앤도마그의 무선 유방 수술 위치 확인 및 림프 추적 솔루션이 추가됩니다. 여기에는 망씨드(Magseed®) 마커, 맥트레이스(Magtrace®) 림프 추적기 및 센티맥(Sentimag®) 플랫폼이 포함됩니다.
이번 통합의 목표는 유방 외과의사와 방사선 의사에게 확대된 옵션과 향상된 사용자 경험을 제공하는 것입니다. 홀로직 유방 및 골격 건강 솔루션의 대통령 에릭 앤더슨(Erik Anderson)은 앤도마그의 혁신적인 기술에 대한 접근성을 증가시키고 환자의 결과를 개선하는 것에 대한 기대감을 표했습니다. 앤도마그의 CEO인 에릭 메이즈(Eric Mayes)는 팀에 대한 기회와 전 세계적으로 더 많은 여성들에게 영향을 미칠 수 있는 잠재력에 대해 낙관적인 시각을 공유했습니다.
Hologic (Nasdaq: HOLX) a finalisé son acquisition d'Endomagnetics (Endomag), un développeur britannique de technologies pour la chirurgie du cancer du sein, pour environ 310 millions de dollars. Cette acquisition ajoute les solutions de localisation de chirurgie mammaire sans fil et de traçage lymphatique d'Endomag au portefeuille chirurgical de Hologic, y compris le marqueur Magseed®, le traceur lymphatique Magtrace® et la plateforme Sentimag®.
L'intégration vise à fournir aux chirurgiens du sein et aux radiologues une gamme élargie d'options et une expérience utilisateur améliorée. Erik Anderson, président des Solutions de santé du sein et du squelette chez Hologic, a exprimé son enthousiasme pour l'augmentation de l'accès aux technologies innovantes d'Endomag et l'amélioration des résultats pour les patients. Eric Mayes, PDG d'Endomag, a partagé son optimisme quant aux opportunités pour son équipe et au potentiel d'impacter davantage de femmes à l'échelle mondiale.
Hologic (Nasdaq: HOLX) hat die Übernahme von Endomagnetics (Endomag), einem in Großbritannien ansässigen Entwickler von Technologien für die Brustkrebschirurgie, für etwa 310 Millionen Dollar abgeschlossen. Diese Übernahme fügt Hologics Portfolio für Brustoperationen die drahtlosen Lösungen von Endomag zur Lokalisierung der Brustchirurgie und zur Lymphverfolgung hinzu, einschließlich des Magseed®-Markers, des Magtrace®-Lymphverfolgers und der Sentimag®-Plattform.
Die Integration zielt darauf ab, Brustchirurgen und Radiologen eine erweiterte Auswahl an Optionen und ein verbessertes Benutzererlebnis zu bieten. Erik Anderson, Präsident von Hologics Lösungen für Brust- und Skelettgesundheit, äußerte sich begeistert über den verbesserten Zugang zu Endomags innovativen Technologien und die Verbesserung der Patientenresultate. Der CEO von Endomag, Eric Mayes, teilte seine Optimismus hinsichtlich der Möglichkeiten für sein Team und das Potenzial, mehr Frauen weltweit zu erreichen.
- Acquisition expands Hologic's breast surgery portfolio with innovative technologies
- Potential for increased market reach and improved patient outcomes
- Complementary technologies may enhance Hologic's competitive position in women's health
- Significant cash outlay of $310 million for the acquisition
Insights
Hologic's $310 million acquisition of Endomagnetics marks a significant expansion in the breast cancer surgery technology market. This move aligns with Hologic's strategy to strengthen its position in women's health, particularly in interventional breast health solutions.
The acquisition is expected to be immediately accretive to Hologic's revenue growth rate and non-GAAP earnings per share. While specific financial projections weren't provided, the integration of Endomag's innovative products like Magseed® marker and Magtrace® lymphatic tracer into Hologic's portfolio could drive substantial revenue growth in the breast health segment.
Investors should note that this acquisition:
- Diversifies Hologic's product offerings in a high-growth market
- Enhances the company's competitive position against rivals like Devicor Medical Products and Merit Medical Systems
- Potentially expands Hologic's international presence, given Endomag's UK base
However, the $310 million price tag is significant and investors should monitor integration costs and the speed at which synergies are realized. The success of this acquisition will largely depend on Hologic's ability to leverage its existing sales channels to accelerate the adoption of Endomag's technologies globally.
The acquisition of Endomagnetics by Hologic represents a significant advancement in breast cancer surgery technologies. Endomag's wireless localization and lymphatic tracing solutions offer several clinical advantages:
1. Improved Precision: The Magseed® marker allows for more accurate tumor localization, potentially reducing the amount of healthy tissue removed during surgery.
2. Enhanced Lymph Node Mapping: The Magtrace® lymphatic tracer provides a radiation-free alternative for sentinel lymph node biopsy, which could improve patient comfort and reduce exposure risks.
Endomagnetics breast cancer surgery technologies (Photo: Business Wire)
“We are thrilled to complete the acquisition of Endomag and are looking forward to working with our new colleagues to increase access to their innovative technologies, which complement and diversify our expanding interventional breast health portfolio,” said Erik Anderson, President of Breast and Skeletal Health Solutions at Hologic. “With our shared commitment to advancing women’s health globally, we are excited to improve outcomes for patients and, together with our customers, redefine the standard of care for breast cancer intervention.”
The transaction adds Endomag’s wireless breast surgery localization and lymphatic tracing solutions – including the Magseed® marker, the Magtrace® lymphatic tracer and the Sentimag® platform – to Hologic’s breast surgery portfolio, providing breast surgeons and radiologists with an expanded range of options and enhanced user experience.
“We are so proud of the company we built and the practice-changing breast surgery technologies that we developed following years of relentless research, innovation and deep engagement with clinicians,” said Eric Mayes, PhD, Chief Executive Officer of Endomag. “As we embark on this new journey with Hologic, I am filled with optimism about the opportunities for our team, our forthcoming innovations and our ability to impact even more women around the world.”
About Hologic
Hologic, Inc. is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnosis and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with us on LinkedIn, Facebook, X (Twitter), Instagram and YouTube.
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about Hologic’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; strategies, positioning, resources, capabilities, and expectations for future performance; and financial outlook and other guidance. These forward-looking statements are based upon assumptions made as of this date and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.
Risks and uncertainties that could adversely affect Hologic’s business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation: the possibility that the anticipated benefits from the transaction or products cannot be fully realized or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of Endomag operations with those of Hologic will be greater than expected; the coverage and reimbursement decisions of third-party payers and the guidelines, recommendations, and studies published by various organizations relating to the use of products and treatments; the ability to successfully manage ongoing organizational and strategic changes, including Hologic’s ability to attract, motivate and retain key employees; the development of new competitive technologies and products; regulatory approvals and clearances for products; the anticipated development of markets in which products are sold into and the success of products in these markets; the anticipated performance and benefits of products; estimated asset and liability values; anticipated trends relating to Hologic’s financial condition or results of operations; and Hologic’s capital resources and the adequacy thereof.
The risks included above are not exhaustive. Other factors that could adversely affect Hologic’s business and prospects are described in Hologic’s filings with the SEC. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
Hologic, The Science of Sure, Magseed, Magtrace and Sentimag are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in
Source: Hologic, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725351417/en/
Media Contact
Bridget Perry
Director, Corporate Communications
(+1) 508.263.8654
bridget.perry@hologic.com
Investor Contact
Ryan Simon
Vice President, Investor Relations
(+1) 858.410.8514
ryan.simon@hologic.com
Source: Hologic, Inc.
FAQ
What is the value of Hologic's acquisition of Endomagnetics ?
What technologies does Endomagnetics bring to Hologic's portfolio?
How does the Endomagnetics acquisition align with Hologic's business strategy?
What is the expected impact of the Endomagnetics acquisition on Hologic's market position?
